PRESS RELEASE published on 07/31/2023 at 18:40, 1 year 3 months ago EQS-Adhoc: APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
PRESS RELEASE published on 07/27/2023 at 22:15, 1 year 3 months ago APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched
PRESS RELEASE published on 07/27/2023 at 22:10, 1 year 3 months ago EQS-Adhoc: APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
PRESS RELEASE published on 07/26/2023 at 23:00, 1 year 3 months ago EV Nickel Announces Completion of NI 43-101 Technical Report for Previously Announced Updated Resource Estimate on the High-Grade W4 Deposit
PRESS RELEASE published on 07/17/2023 at 13:00, 1 year 4 months ago EV Nickel Announces Non-Brokered Private Placement of up to C$1.0 Million
PRESS RELEASE published on 07/10/2023 at 13:50, 1 year 4 months ago APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor
PRESS RELEASE published on 07/10/2023 at 13:45, 1 year 4 months ago EQS-Adhoc: APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
PRESS RELEASE published on 06/29/2023 at 07:30, 1 year 4 months ago APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023
PRESS RELEASE published on 06/12/2023 at 13:00, 1 year 5 months ago EV Nickel Updates Resource Estimate on the High-Grade W4 Deposit- More Than Doubles 2010 Historical Estimate
PRESS RELEASE published on 05/15/2023 at 13:00, 1 year 6 months ago EV Nickel W4 Met Sample Drill Results Include- 71.9m Grading 0.97% Ni with 4.0m Grading 4.00% Ni and 13.0m Grading 1.87% Ni
Published on 11/21/2024 at 22:05, 1 hour 9 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 24 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 59 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 4 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 14 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 4 hours 13 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 38 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 16 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 23 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 23 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 16 hours 16 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
